厄贝沙坦氢氯噻嗪联合美托洛尔治疗老年重症心力衰竭的效果(5)
[25]Mancia G，Fagard R，Narkiewicz K，et al.2013 ESH/ESC Guidelines for the management of arterial hypertension：the task force for the management of arterial hypertension of the European Society of Hypertension(ESH)and of the European Society of Cardiology(ESC)[J].Blood Pressure，2014，23(1)：3-16.
[26]Ettore M，Stefano O，Gianfranco P.Blood pressure response to zofenopril or irbesartan each combined with hydrochlorothiazide in high-risk hypertensives uncontrolled by monotherapy：a Randomized，double-Blind，controlled，parallel group，noninferiority trial[J].Int J Hypertens，2015，8(5)：139 465.
[27]Molenaar P，Christ T，Hussain RI，et al.PDE3，but not PDE4，reduces β1- and β2-adrenoceptor-mediated inotropic and lusitropic effects in failing ventricle from metoprolol-treated patients[J].Br J Pharmacol，2013，169(3)：528-538.
[28]Ajam T，Ajam S，Devaraj S，et al.Effect on mortality of higher versus lower β-blocker(metoprolol succinate or carvedilol)dose inpatients with heart failure[J].Am J Cardiol，2018，122(6)：994-998.
[29]Peter Bramlage.Fixed combination of irbesartan and hydroch lorothiazide in the management of hypertension[J].Vasc Health Risk Manag，2009，5(1)：213-224.
(收稿日期：2018-10-23 本文編辑：闫 佩), 百拇医药(黄舒伟 姚为学 宋智 柯道 柯子奋)
[26]Ettore M，Stefano O，Gianfranco P.Blood pressure response to zofenopril or irbesartan each combined with hydrochlorothiazide in high-risk hypertensives uncontrolled by monotherapy：a Randomized，double-Blind，controlled，parallel group，noninferiority trial[J].Int J Hypertens，2015，8(5)：139 465.
[27]Molenaar P，Christ T，Hussain RI，et al.PDE3，but not PDE4，reduces β1- and β2-adrenoceptor-mediated inotropic and lusitropic effects in failing ventricle from metoprolol-treated patients[J].Br J Pharmacol，2013，169(3)：528-538.
[28]Ajam T，Ajam S，Devaraj S，et al.Effect on mortality of higher versus lower β-blocker(metoprolol succinate or carvedilol)dose inpatients with heart failure[J].Am J Cardiol，2018，122(6)：994-998.
[29]Peter Bramlage.Fixed combination of irbesartan and hydroch lorothiazide in the management of hypertension[J].Vasc Health Risk Manag，2009，5(1)：213-224.
(收稿日期：2018-10-23 本文編辑：闫 佩), 百拇医药(黄舒伟 姚为学 宋智 柯道 柯子奋)